| 1 | Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials | 0.5 | 23 | Citations (PDF) |
| 2 | Predicting cognitive decline from neuropsychiatric symptoms and Alzheimer's disease biomarkers: A machine learning approach to a population-based data | 2.6 | 5 | Citations (PDF) |
| 3 | Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum | 17.6 | 5 | Citations (PDF) |
| 4 | Association of plasma biomarkers of Alzheimer’s pathology and neurodegeneration with gait performance in older adults | 4.5 | 7 | Citations (PDF) |
| 5 | Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations | 1.0 | 27 | Citations (PDF) |
| 6 | White matter hyperintensities and TDP‐43 pathology in Alzheimer's disease | 0.5 | 2 | Citations (PDF) |
| 7 | Identifying gait differences between Alzheimer's disease and dementia with Lewy bodies and their associations with regional amyloid deposition | 0.5 | 5 | Citations (PDF) |
| 8 | Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET | 0.5 | 2 | Citations (PDF) |
| 9 | Brain tissue metal concentrations and Alzheimer’s disease neuropathology in total joint arthroplasty patients versus controls | 9.2 | 1 | Citations (PDF) |
| 10 | Patterns of Factors in the National Institute on Aging Health Disparities Research Framework Domains and Mild Cognitive Impairment Risk | 1.4 | 3 | Citations (PDF) |
| 11 | Eligibility for donanemab trial in a population-based study of cognitive aging | 2.8 | 3 | Citations (PDF) |
| 12 | Usability of the Mayo Test Drive remote self-administered web-based cognitive screening battery in adults aged 35–100 with and without cognitive impairment | 1.0 | 3 | Citations (PDF) |
| 13 | Multiple Neuropathologies Underly Hippocampal Subfield Atrophy in a Case With a Slowly Progressive Amnestic Syndrome: Challenging the Notion of Pure LATE‐NC | 1.2 | 1 | Citations (PDF) |
| 14 | Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET | 0.5 | 3 | Citations (PDF) |
| 15 | White matter hyperintensities in dementia with lewy bodies and posterior cortical atrophy | 3.4 | 1 | Citations (PDF) |
| 16 | Mayo Normative Studies: Regression-based normative data for remote self-administration of the Stricker Learning Span, Symbols Test, and Mayo Test Drive Screening Battery Composite and validation in individuals with mild cognitive impairment and dementia | 2.7 | 4 | Citations (PDF) |
| 17 | High resolution autoradiography of [18F]MK-6240 and [18F]Flortaucipir shows similar neurofibrillary tangle binding patterns preferentially recognizing middling neurofibrillary tangle maturity | 9.2 | 3 | Citations (PDF) |
| 18 | Genome-wide association study of neuropathological features in Lewy body diseaseBrain, 2025, 148, 2785-2796 | 8.4 | 2 | Citations (PDF) |
| 19 | APOE genotype determines cell-type-specific pathological landscape of Alzheimer’s diseaseNeuron, 2025, 113, 1380-1397.e7 | 11.0 | 18 | Citations (PDF) |
| 20 | Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials | 14.5 | 45 | Citations (PDF) |
| 21 | Approaches to Timescale Choice in Cognitive Aging Research and Potential Implications for Estimated Exposure Effects: Coordinated Analyses in 10 Cohorts of Older Adults | 2.8 | 3 | Citations (PDF) |
| 22 | Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire | 3.6 | 4 | Citations (PDF) |
| 23 | Longitudinal Evolution of Posterior Cortical Atrophy | 1.0 | 3 | Citations (PDF) |
| 24 | Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease | 6.1 | 8 | Citations (PDF) |
| 25 | Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing | 13.7 | 8 | Citations (PDF) |
| 26 | 2024 Alzheimer's Association criteria for Alzheimer's disease diagnosis are usually anchored to both plaques and tangles, not Aβ alone | 0.5 | 2 | Citations (PDF) |
| 27 | Cortical microstructural abnormalities in dementia with Lewy bodies and their associations with Alzheimer’s disease copathologies | 7.0 | 4 | Citations (PDF) |
| 28 | Analysis of the splicing landscape of the frontal cortex in FTLD-TDP reveals subtype specific patterns and cryptic splicing | 9.2 | 3 | Citations (PDF) |
| 29 | Impact of cardiovascular risk factors on plasma biomarkers in prediction of Alzheimer's and cerebrovascular neuropathology | 2.8 | 5 | Citations (PDF) |
| 30 | Associations between temporal lobe cortical NODDI measures and memory function in individuals without clinical dementia | 0.5 | 1 | Citations (PDF) |
| 31 | Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity | 16.6 | 25 | Citations (PDF) |
| 32 | Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts | 0.5 | 5 | Citations (PDF) |
| 33 | An FDG-PET–Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders | 1.0 | 9 | Citations (PDF) |
| 34 | Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance | 0.5 | 1 | Citations (PDF) |
| 35 | Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT‐AD) | 0.5 | 0 | Citations (PDF) |
| 36 | Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer’s disease | 8.1 | 5 | Citations (PDF) |
| 37 | Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition | 2.8 | 1 | Citations (PDF) |
| 38 | Brain transcriptomics highlight abundant gene expression and splicing alterations in non-neuronal cells in aFTLD-U | 9.2 | 1 | Citations (PDF) |
| 39 | Evaluation and interpretation of DTI-ALPS, a proposed surrogate marker for glymphatic clearance, in a large population-based sample | 6.6 | 6 | Citations (PDF) |
| 40 | <sup>18</sup>F‐FDG PET in detection of primary age‐related tauopathy (PART) – Is there a role? Insights from an imaging‐pathology correlation study | 0.5 | 0 | Citations (PDF) |
| 41 | Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals | 0.5 | 2 | Citations (PDF) |
| 42 | The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022 | 0.5 | 69 | Citations (PDF) |
| 43 | Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseasesBrain, 2024, 147, 1483-1496 | 8.4 | 5 | Citations (PDF) |
| 44 | Synthesizing images of tau pathology from cross-modal neuroimaging using deep learningBrain, 2024, 147, 980-995 | 8.4 | 13 | Citations (PDF) |
| 45 | Vascular risk, gait, behavioral, and plasma indicators of VCID | 0.5 | 11 | Citations (PDF) |
| 46 | Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET | 0.5 | 26 | Citations (PDF) |
| 47 | Neuroimaging Characteristics of Hearing Loss in the Mayo Clinic Study of Aging | 2.3 | 5 | Citations (PDF) |
| 48 | Assessing network degeneration and phenotypic heterogeneity in genetic frontotemporal lobar degeneration by decoding FDG-PET | 3.3 | 0 | Citations (PDF) |
| 49 | Significance of a positive tau PET scan with a negative amyloid PET scan | 0.5 | 6 | Citations (PDF) |
| 50 | TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia | 12.5 | 25 | Citations (PDF) |
| 51 | Machine Learning Models of Polygenic Risk for Enhanced Prediction of Alzheimer Disease Endophenotypes | 2.8 | 12 | Citations (PDF) |
| 52 | Longitudinal default mode sub-networks in the language and visual variants of Alzheimer’s disease | 3.6 | 7 | Citations (PDF) |
| 53 | Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals | 0.5 | 32 | Citations (PDF) |
| 54 | A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants | 2.8 | 9 | Citations (PDF) |
| 55 | Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology | 2.5 | 14 | Citations (PDF) |
| 56 | Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies | 0.5 | 34 | Citations (PDF) |
| 57 | Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease | 5.0 | 11 | Citations (PDF) |
| 58 | Altered structural and functional connectivity in Posterior Cortical Atrophy and Dementia with Lewy bodies | 4.4 | 15 | Citations (PDF) |
| 59 | Clinicoradiological and neuropathological evaluation of primary progressive aphasia | 6.3 | 10 | Citations (PDF) |
| 60 | Role of GBA variants in Lewy body disease neuropathology | 9.2 | 13 | Citations (PDF) |
| 61 | HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases | 14.1 | 21 | Citations (PDF) |
| 62 | A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors | 6.6 | 14 | Citations (PDF) |
| 63 | CSF biomarkers of immune activation and Alzheimer’s disease for predicting cognitive impairment risk in the elderly | 10.9 | 22 | Citations (PDF) |
| 64 | Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies | 7.0 | 6 | Citations (PDF) |
| 65 | Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease | 17.6 | 14 | Citations (PDF) |
| 66 | Prescription Opioids and Brain Structure in Community-Dwelling Older Adults | 3.7 | 7 | Citations (PDF) |
| 67 | Boston Criteria v2.0 for Cerebral Amyloid Angiopathy Without Hemorrhage | 1.0 | 25 | Citations (PDF) |
| 68 | Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease | 2.8 | 15 | Citations (PDF) |
| 69 | TDP-43 Is Associated with Subiculum and Cornu Ammonis 1 Hippocampal Subfield Atrophy in Primary Age-Related Tauopathy | 2.6 | 6 | Citations (PDF) |
| 70 | Case report: pre-symptomatic clinical and metabolic profile in posterior cortical atrophy and dementia with Lewy bodies | 0.7 | 0 | Citations (PDF) |
| 71 | Patterns of Early Neocortical Amyloid-β Accumulation: A PET Population-Based Study | 5.5 | 12 | Citations (PDF) |
| 72 | Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force | 2.8 | 15 | Citations (PDF) |
| 73 | Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia | 6.5 | 10 | Citations (PDF) |
| 74 | Gliovascular transcriptional perturbations in Alzheimer’s disease reveal molecular mechanisms of blood brain barrier dysfunction | 13.7 | 26 | Citations (PDF) |
| 75 | Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice | 3.7 | 3 | Citations (PDF) |
| 76 | Speech-language within and between network disruptions in primary progressive aphasia variants | 3.3 | 5 | Citations (PDF) |
| 77 | Can white matter hyperintensities based Fazekas visual assessment scales inform about Alzheimer’s disease pathology in the population? | 6.6 | 19 | Citations (PDF) |
| 78 | Mayo Normative Studies: Amyloid and Neurodegeneration Negative Normative Data for the Auditory Verbal Learning Test and Sex-Specific Sensitivity to Mild Cognitive Impairment/Dementia | 2.6 | 4 | Citations (PDF) |
| 79 | Association of Anxiety and Unspecified Emotional Distress Obtained from a Medical Records Linkage System with Incident Cognitive Outcomes in a Population-Based Setting | 2.6 | 1 | Citations (PDF) |
| 80 | Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome | 3.6 | 28 | Citations (PDF) |
| 81 | Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays | 0.5 | 54 | Citations (PDF) |
| 82 | Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model | 0.5 | 34 | Citations (PDF) |
| 83 | Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease | 12.5 | 21 | Citations (PDF) |
| 84 | Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure | 5.5 | 7 | Citations (PDF) |
| 85 | NODDI in gray matter is a sensitive marker of aging and early AD changes | 2.5 | 11 | Citations (PDF) |
| 86 | The Alzheimer's Disease Neuroimaging Initiative Clinical Core | 0.5 | 12 | Citations (PDF) |
| 87 | The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research | 0.5 | 11 | Citations (PDF) |
| 88 | Can integration of Alzheimer’s plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction? | 3.6 | 4 | Citations (PDF) |
| 89 | Validating a Portable, Camera-Based System to Scale the Clinical Gait Assessment as a Tele-Health Solution | 1.7 | 0 | Citations (PDF) |
| 90 | CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET | 13.7 | 7 | Citations (PDF) |
| 91 | Non-rapid eye movement sleep slow-wave activity features are associated with amyloid accumulation in older adults with obstructive sleep apnoea | 3.6 | 6 | Citations (PDF) |
| 92 | Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers | 0.5 | 16 | Citations (PDF) |
| 93 | Taxonomic intestinal microbiota differences in Lewy body spectrum disease and cohabitant controls | 2.6 | 1 | Citations (PDF) |
| 94 | Investigating the feasibility of 18F‐flortaucipir PET imaging in the antemortem diagnosis of primary age‐related tauopathy (PART): An observational imaging‐pathological study | 0.5 | 3 | Citations (PDF) |
| 95 | Characterizing the progression from mild cognitive impairment to dementia: a network analysis of longitudinal clinical visits | 3.2 | 4 | Citations (PDF) |
| 96 | Self‐reported physical activity and gait in older adults without dementia: A longitudinal study | 1.6 | 3 | Citations (PDF) |
| 97 | Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability | 14.5 | 64 | Citations (PDF) |
| 98 | Impact of alcohol use disorder on cognition in correlation with aging: a community-based retrospective cohort study | 1.7 | 6 | Citations (PDF) |
| 99 | Clinical criteria for a limbic‐predominant amnestic neurodegenerative syndrome highly associated with TDP‐43 and slow clinical progression | 0.5 | 0 | Citations (PDF) |
| 100 | Preserved transcriptional networks in immune signaling pathways associated with chronic disease identified in Alzheimer’s disease and Parkinson’s disease, cross‐tissue analysis | 0.5 | 0 | Citations (PDF) |
| 101 | Chronic Medical Conditions and Dementia Risk: Brain Age Models for Quantifying Impact and Understanding Mechanisms | 0.5 | 0 | Citations (PDF) |
| 102 | CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly | 0.5 | 0 | Citations (PDF) |
| 103 | Plasma and MRI biomarkers predict post‐mortem tau pathology | 0.5 | 1 | Citations (PDF) |
| 104 | Chronic Medical Conditions and Dementia Risk: Brain Age Models for Quantifying Impact and Understanding Mechanisms | 0.5 | 0 | Citations (PDF) |
| 105 | The Alzheimer’s Tau Platform (ATP): a Phase 2, combination amyloid and tau therapy clinical trial for early AD | 0.5 | 3 | Citations (PDF) |
| 106 | Variational autoencoder latent space as a robust and pragmatic clinical classification tool for dementia | 0.5 | 0 | Citations (PDF) |
| 107 | Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging | 0.5 | 40 | Citations (PDF) |
| 108 | Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers | 3.5 | 0 | Citations (PDF) |
| 109 | Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration | 2.6 | 4 | Citations (PDF) |
| 110 | Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4 | 0.5 | 108 | Citations (PDF) |
| 111 | The many faces of globular glial tauopathy: A clinical and imaging study | 3.5 | 18 | Citations (PDF) |
| 112 | TDP‐43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease | 0.5 | 12 | Citations (PDF) |
| 113 | Mayo‐PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures to facilitate clinical translation | 0.5 | 17 | Citations (PDF) |
| 114 | Item Response Analysis of the Financial Capacity Instrument-Short Form | 0.4 | 1 | Citations (PDF) |
| 115 | Natural cubic splines for the analysis of Alzheimer's clinical trials | 1.2 | 26 | Citations (PDF) |
| 116 | Differential effect of dementia etiology on cortical stiffness as assessed by MR elastography | 3.3 | 15 | Citations (PDF) |
| 117 | Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease | 2.8 | 17 | Citations (PDF) |
| 118 | Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline | 2.0 | 12 | Citations (PDF) |
| 119 | Association between physical activity and longitudinal change in body mass index in middle-aged and older adults | 3.1 | 13 | Citations (PDF) |
| 120 | Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease | 2.6 | 13 | Citations (PDF) |
| 121 | Predicting amyloid PET and tau PET stages with plasma biomarkersBrain, 2023, 146, 2029-2044 | 8.4 | 120 | Citations (PDF) |
| 122 | Population-Based Evaluation of Total Protein in Cerebrospinal Fluid | 3.7 | 15 | Citations (PDF) |
| 123 | Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer’s Disease and Vascular Pathology | 2.6 | 5 | Citations (PDF) |
| 124 | Default mode network failure and neurodegeneration across aging and amnestic and dysexecutive Alzheimer’s disease | 3.6 | 14 | Citations (PDF) |
| 125 | Lecanemab: Appropriate Use Recommendations | 2.8 | 495 | Citations (PDF) |
| 126 | White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease | 1.0 | 24 | Citations (PDF) |
| 127 | Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease | 2.5 | 9 | Citations (PDF) |
| 128 | Cross–scanner harmonization methods for structural MRI may need further work: A comparison study | 4.4 | 36 | Citations (PDF) |
| 129 | Comparison of Clinical, Genetic, and Pathologic Features of Limbic and Diffuse Transactive Response DNA-Binding Protein 43 Pathology in Alzheimer’s Disease Neuropathologic Spectrum | 2.6 | 5 | Citations (PDF) |
| 130 | Corrigendum to “Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort” [Clin. Chim. Acta 535 (2022) 153-156] | 1.5 | 1 | Citations (PDF) |
| 131 | Evidence against a temporal association between cerebrovascular disease and Alzheimer’s disease imaging biomarkers | 13.7 | 21 | Citations (PDF) |
| 132 | Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome | 1.0 | 36 | Citations (PDF) |
| 133 | Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change | 9.2 | 27 | Citations (PDF) |
| 134 | Diffusivity Changes in Posterior Cortical Atrophy and Logopenic Progressive Aphasia: A Longitudinal Diffusion Tensor Imaging Study | 2.6 | 5 | Citations (PDF) |
| 135 | Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosisBrain, 2023, 146, 4508-4519 | 8.4 | 22 | Citations (PDF) |
| 136 | Association of Polysomnographic Sleep Parameters With Neuroimaging Biomarkers of Cerebrovascular Disease in Older Adults With Sleep Apnea | 1.0 | 21 | Citations (PDF) |
| 137 | β-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies | 1.0 | 26 | Citations (PDF) |
| 138 | A face-off of MRI research sequences by their need for de-facing | 4.4 | 17 | Citations (PDF) |
| 139 | Plasma‐derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community‐based study | 2.5 | 8 | Citations (PDF) |
| 140 | Association of Plasma Biomarkers of Alzheimer Disease With Cognition and Medical Comorbidities in a Biracial Cohort | 1.0 | 72 | Citations (PDF) |
| 141 | Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging | 1.0 | 119 | Citations (PDF) |
| 142 | Characterizing Performance Gaps of a Code-Based Dementia Algorithm in a Population-Based Cohort of Cognitive Aging | 2.6 | 2 | Citations (PDF) |
| 143 | Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial | 33.0 | 192 | Citations (PDF) |
| 144 | TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains | 14.1 | 46 | Citations (PDF) |
| 145 | Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening | 6.6 | 29 | Citations (PDF) |
| 146 | Effects of de-facing software mri_reface on utility of imaging biomarkers used in Alzheimer’s disease research | 3.3 | 4 | Citations (PDF) |
| 147 | A New Framework for Dementia Nomenclature | 17.6 | 34 | Citations (PDF) |
| 148 | Association of Cerebrovascular Imaging Biomarkers, Depression, and Anxiety, with Mild Cognitive Impairment | 2.3 | 2 | Citations (PDF) |
| 149 | Clinicopathologic features of a novel star-shaped transactive response DNA-binding protein 43 (TDP-43) pathology in the oldest old | 1.8 | 7 | Citations (PDF) |
| 150 | Comparing approaches based on the global functional organization of the brain versus local connectivity to predict tau‐PET across the Alzheimer’s disease phenotypic spectrum | 0.5 | 0 | Citations (PDF) |
| 151 | Curriculum‐based CME Programming Results in Comprehensive Improvements in Knowledge, Competence, and Confidence in Diagnosing Early Forms of Alzheimer’s Disease Among a Global Audience of PCPs and Neurologists | 0.5 | 0 | Citations (PDF) |
| 152 | Accelerated aging in gait patterns is a leading indicator for cognitive decline | 0.5 | 0 | Citations (PDF) |
| 153 | Curriculum‐based CME Programming Results in Comprehensive Improvements in Knowledge, Competence, and Confidence in Diagnosing Early Forms of Alzheimer’s Disease Among a Global Audience of PCPs and Neurologists | 0.5 | 0 | Citations (PDF) |
| 154 | Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease | 0.5 | 140 | Citations (PDF) |
| 155 | Regional Brain Stiffness Analysis of Dementia with Lewy Bodies | 3.4 | 2 | Citations (PDF) |
| 156 | Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases | 8.4 | 94 | Citations (PDF) |
| 157 | Cerebrospinal fluid dynamics and discordant amyloid biomarkers | 3.4 | 16 | Citations (PDF) |
| 158 | Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network | 2.6 | 6 | Citations (PDF) |
| 159 | Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual | 2.6 | 1 | Citations (PDF) |
| 160 | Clinical Deep Phenotyping of
ABCA7
Mutation Carriers | 2.8 | 13 | Citations (PDF) |
| 161 | Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk | 3.6 | 47 | Citations (PDF) |
| 162 | 1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults | 3.4 | 23 | Citations (PDF) |
| 163 | TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration | 3.3 | 13 | Citations (PDF) |
| 164 | Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration | 3.6 | 30 | Citations (PDF) |
| 165 | Association of Performance on the Financial Capacity Instrument–Short Form With Brain Amyloid Load and Cortical Thickness in Older Adults | 2.0 | 5 | Citations (PDF) |
| 166 | White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition | 5.0 | 39 | Citations (PDF) |
| 167 | Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology | 2.5 | 79 | Citations (PDF) |
| 168 | TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A | 37.9 | 449 | Citations (PDF) |
| 169 | Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer’s disease: a series of clinical cases | 3.4 | 9 | Citations (PDF) |
| 170 | Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease | 13.7 | 34 | Citations (PDF) |
| 171 | Reply to A Letter Concerning “Aducanumab: What About the Patient?” | 6.6 | 0 | Citations (PDF) |
| 172 | Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies | 4.6 | 19 | Citations (PDF) |
| 173 | Poly (ADP-Ribose) and α–synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity | 2.3 | 17 | Citations (PDF) |
| 174 | Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutationsBrain, 2022, 145, 2472-2485 | 8.4 | 19 | Citations (PDF) |
| 175 | Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer’s disease | 9.2 | 8 | Citations (PDF) |
| 176 | Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease | 17.6 | 66 | Citations (PDF) |
| 177 | Deep learning-based brain age prediction in normal aging and dementia | 14.5 | 173 | Citations (PDF) |
| 178 | Artificial Intelligence–Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts | 3.7 | 16 | Citations (PDF) |
| 179 | Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds | 2.6 | 16 | Citations (PDF) |
| 180 | Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiologyBrain, 2022, 145, 3594-3607 | 8.4 | 49 | Citations (PDF) |
| 181 | Performance of plasma phosphorylated tau 181 and 217 in the community | 33.0 | 340 | Citations (PDF) |
| 182 | CSF phosphorylated tau as an indicator of subsequent tau accumulation | 3.4 | 7 | Citations (PDF) |
| 183 | Face recognition from research brain PET: An unexpected PET problem | 4.4 | 20 | Citations (PDF) |
| 184 | Causal structure discovery identifies risk factors and early brain markers related to evolution of white matter hyperintensities | 3.3 | 18 | Citations (PDF) |
| 185 | Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis | 3.5 | 8 | Citations (PDF) |
| 186 | Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease | 2.5 | 12 | Citations (PDF) |
| 187 | Area Deprivation Index as a Surrogate of Resilience in Aging and Dementia | 2.2 | 27 | Citations (PDF) |
| 188 | Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI | 9.2 | 15 | Citations (PDF) |
| 189 | Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity | 4.0 | 19 | Citations (PDF) |
| 190 | Polygenic Scores of Alzheimer’s Disease Risk Genes Add Only Modestly to
APOE
in Explaining Variation in Amyloid PET Burden | 2.6 | 7 | Citations (PDF) |
| 191 | Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures | 5.0 | 2 | Citations (PDF) |
| 192 | Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging | 1.6 | 8 | Citations (PDF) |
| 193 | Association of blood pressure variability with short- and long-term cognitive outcomes in patients with critical illness | 2.3 | 5 | Citations (PDF) |
| 194 | Evidence of cerebellar TDP-43 loss of function in FTLD-TDP | 5.0 | 15 | Citations (PDF) |
| 195 | Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument‐Short Form | 2.5 | 9 | Citations (PDF) |
| 196 | Temporal Cortical Thickness and Cognitive Associations among Typical and Atypical Phenotypes of Alzheimer’s Disease | 2.3 | 7 | Citations (PDF) |
| 197 | Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography | 6.6 | 6 | Citations (PDF) |
| 198 | Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease | 3.4 | 14 | Citations (PDF) |
| 199 | Regional white matter hyperintensities in posterior cortical atrophy and logopenic progressive aphasia | 3.4 | 9 | Citations (PDF) |
| 200 | Plasma neurofilament light chain (NfL) reference interval determination in an Age-stratified cognitively unimpaired cohort | 1.5 | 38 | Citations (PDF) |
| 201 | Blood pressure changes impact corticospinal integrity and downstream gait and balance control | 3.4 | 4 | Citations (PDF) |
| 202 | Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites | 2.8 | 1 | Citations (PDF) |
| 203 | Distinct brain iron profiles associated with logopenic progressive aphasia and posterior cortical atrophy | 3.3 | 12 | Citations (PDF) |
| 204 | Caspase-2 mRNA levels are not elevated in mild cognitive impairment, Alzheimer’s disease, Huntington’s disease, or Lewy Body dementia | 2.3 | 3 | Citations (PDF) |
| 205 | Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old | 2.6 | 5 | Citations (PDF) |
| 206 | Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline | 33.0 | 362 | Citations (PDF) |
| 207 | Long-term Cognitive Trajectory After Total Joint Arthroplasty | 6.6 | 15 | Citations (PDF) |
| 208 | Association between hearing loss and development of dementia using formal behavioural audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-based study | 10.3 | 47 | Citations (PDF) |
| 209 | Single Cell Approaches Reveal Perturbed Brain Vascular Molecules in Alzheimer’s Disease | 0.5 | 0 | Citations (PDF) |
| 210 | Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels | 14.1 | 40 | Citations (PDF) |
| 211 | Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder | 3.6 | 15 | Citations (PDF) |
| 212 | Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging | 1.7 | 39 | Citations (PDF) |
| 213 | Association of Hospitalization with Long‐Term Cognitive Trajectories in Older Adults | 2.9 | 32 | Citations (PDF) |
| 214 | Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers | 4.4 | 103 | Citations (PDF) |
| 215 | Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment | 17.6 | 52 | Citations (PDF) |
| 216 | Brain MRI after critical care admission: A longitudinal imaging study | 2.3 | 12 | Citations (PDF) |
| 217 | Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging | 2.6 | 21 | Citations (PDF) |
| 218 | The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia | 3.4 | 17 | Citations (PDF) |
| 219 | Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel | 17.6 | 250 | Citations (PDF) |
| 220 | Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia | 2.3 | 17 | Citations (PDF) |
| 221 | P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status | 2.5 | 66 | Citations (PDF) |
| 222 | β-Amyloid PET and
123
I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia | 1.0 | 25 | Citations (PDF) |
| 223 | FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD | 3.3 | 48 | Citations (PDF) |
| 224 | Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects | 2.4 | 12 | Citations (PDF) |
| 225 | Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers | 3.6 | 73 | Citations (PDF) |
| 226 | Gait Speed and Instrumental Activities of Daily Living in Older Adults After Hospitalization: A Longitudinal Population-Based Study | 3.5 | 4 | Citations (PDF) |
| 227 | Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimer’s pathophysiology | 5.0 | 29 | Citations (PDF) |
| 228 | National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome | 1.0 | 277 | Citations (PDF) |
| 229 | TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death | 2.6 | 13 | Citations (PDF) |
| 230 | Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging | 2.2 | 45 | Citations (PDF) |
| 231 | White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline | 3.6 | 35 | Citations (PDF) |
| 232 | NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages | 6.6 | 63 | Citations (PDF) |
| 233 | Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition | 3.6 | 77 | Citations (PDF) |
| 234 | Long-read targeted sequencing uncovers clinicopathological associations forC9orf72-linked diseasesBrain, 2021, 144, 1082-1088 | 8.4 | 29 | Citations (PDF) |
| 235 | Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease | 17.6 | 241 | Citations (PDF) |
| 236 | Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s disease | 13.7 | 74 | Citations (PDF) |
| 237 | Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes | 2.6 | 16 | Citations (PDF) |
| 238 | Alzheimer disease | 47.2 | 1,991 | Citations (PDF) |
| 239 | MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease | 2.2 | 26 | Citations (PDF) |
| 240 | Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives | 4.4 | 75 | Citations (PDF) |
| 241 | CSF dynamics as a predictor of cognitive progression | 4.4 | 8 | Citations (PDF) |
| 242 | Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging | 2.6 | 5 | Citations (PDF) |
| 243 | Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networksBrain, 2021, 144, 3212-3225 | 8.4 | 47 | Citations (PDF) |
| 244 | Cerebral Microbleeds | 6.0 | 17 | Citations (PDF) |
| 245 | Lack of physical activity, neuropsychiatric symptoms and the risk of incident mild cognitive impairment in older community-dwelling individuals | 1.1 | 9 | Citations (PDF) |
| 246 | Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET | 3.6 | 21 | Citations (PDF) |
| 247 | Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal | 1.0 | 19 | Citations (PDF) |
| 248 | Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease | 13.7 | 86 | Citations (PDF) |
| 249 | Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation | 4.4 | 38 | Citations (PDF) |
| 250 | Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes | 17.6 | 212 | Citations (PDF) |
| 251 | Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2 | 2.6 | 15 | Citations (PDF) |
| 252 | A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer’s Disease Based on Cogstate One Card Learning Accuracy Performance | 2.6 | 10 | Citations (PDF) |
| 253 | APOE3
-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia | 12.5 | 81 | Citations (PDF) |
| 254 | Sex Difference in the Relation Between Marital Status and Dementia Risk in Two Population-Based Cohorts | 2.6 | 15 | Citations (PDF) |
| 255 | Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies | 3.4 | 34 | Citations (PDF) |
| 256 | Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study | 5.2 | 53 | Citations (PDF) |
| 257 | Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model | 4.4 | 31 | Citations (PDF) |
| 258 | Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population | 3.6 | 19 | Citations (PDF) |
| 259 | Reply to “Thinking beyond Aducanumab Controversy” | 6.6 | 0 | Citations (PDF) |
| 260 | Androgen Deprivation Therapy Use and Risk of Mild Cognitive Impairment in Prostate Cancer Patients | 1.3 | 8 | Citations (PDF) |
| 261 | White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging | 2.5 | 1 | Citations (PDF) |
| 262 | Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial | 2.8 | 115 | Citations (PDF) |
| 263 | Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes | 6.6 | 57 | Citations (PDF) |
| 264 | The screening and enrollment of underrepresented ethnoracial and educational populations in the Alzheimer's Disease Neuroimaging Initiative | 0.5 | 1 | Citations (PDF) |
| 265 | Successful cognitive aging definitions and associated demographic, biomarker profiles and lifestyles in the 80+ MCSA population | 0.5 | 0 | Citations (PDF) |
| 266 | Linear vs volume measures of ventricle size | 1.0 | 38 | Citations (PDF) |
| 267 | Cerebral microbleed incidence, relationship to amyloid burden | 1.0 | 40 | Citations (PDF) |
| 268 | Prostate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment | 1.3 | 7 | Citations (PDF) |
| 269 | Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech | 2.9 | 7 | Citations (PDF) |
| 270 | β-Amyloid PET and neuropathology in dementia with Lewy bodies | 1.0 | 95 | Citations (PDF) |
| 271 | β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies | 1.0 | 111 | Citations (PDF) |
| 272 | Predicting future rates of tau accumulation on PETBrain, 2020, 143, 3136-3150 | 8.4 | 98 | Citations (PDF) |
| 273 | Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI | 3.4 | 57 | Citations (PDF) |
| 274 | Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition | 3.6 | 19 | Citations (PDF) |
| 275 | Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation | 6.1 | 115 | Citations (PDF) |
| 276 | Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy | 5.0 | 14 | Citations (PDF) |
| 277 | Association Between Neuropsychiatric Symptoms and Functional Change in Older Non-Demented Adults: Mayo Clinic Study of Aging | 2.6 | 7 | Citations (PDF) |
| 278 | Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes | 6.0 | 13 | Citations (PDF) |
| 279 | NIA‐AA AD framework stage 2: Performance in the community | 0.5 | 0 | Citations (PDF) |
| 280 | MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features | 5.0 | 17 | Citations (PDF) |
| 281 | Protein contributions to brain atrophy acceleration in Alzheimer’s disease and primary age-related tauopathyBrain, 2020, 143, 3463-3476 | 8.4 | 66 | Citations (PDF) |
| 282 | Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions | 3.7 | 49 | Citations (PDF) |
| 283 | Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes | 3.6 | 120 | Citations (PDF) |
| 284 | Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy | 1.0 | 58 | Citations (PDF) |
| 285 | Longitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypesBrain, 2020, 143, 2281-2294 | 8.4 | 78 | Citations (PDF) |
| 286 | Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer’s Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment | 2.6 | 37 | Citations (PDF) |
| 287 | Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution | 1.0 | 87 | Citations (PDF) |
| 288 | Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults | 4.9 | 18 | Citations (PDF) |
| 289 | Preoperative cognitive impairment associated with oversedation during recovery from anesthesia | 1.4 | 4 | Citations (PDF) |
| 290 | Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly | 1.0 | 38 | Citations (PDF) |
| 291 | CSF biomarkers in Olmsted County | 1.0 | 16 | Citations (PDF) |
| 292 | Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia | 3.4 | 4 | Citations (PDF) |
| 293 | 18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies | 3.6 | 26 | Citations (PDF) |
| 294 | A soluble truncated tau species related to cognitive dysfunction is elevated in the brain of cognitively impaired human individuals | 3.4 | 30 | Citations (PDF) |
| 295 | Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults | 1.0 | 29 | Citations (PDF) |
| 296 | Medical Doctors and Dementia: A Longitudinal Study | 2.9 | 1 | Citations (PDF) |
| 297 | Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis | 6.6 | 23 | Citations (PDF) |
| 298 | Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging | 4.0 | 36 | Citations (PDF) |
| 299 | Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer’s Disease Neuropathological Changes | 2.6 | 27 | Citations (PDF) |
| 300 | TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease | 3.4 | 10 | Citations (PDF) |
| 301 | Exposure to surgery with regional anesthesia and cortical thickness in older adults | 4.8 | 0 | Citations (PDF) |
| 302 | MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous | 3.8 | 19 | Citations (PDF) |
| 303 | Brain amyloid, cortical thickness, and changes in activities of daily living | 3.8 | 4 | Citations (PDF) |
| 304 | Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer’s disease: a case-control study | 3.4 | 17 | Citations (PDF) |
| 305 | Pick’s disease: clinicopathologic characterization of 21 cases | 3.4 | 24 | Citations (PDF) |
| 306 | Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging | 3.4 | 4 | Citations (PDF) |
| 307 | Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia | 10.6 | 199 | Citations (PDF) |
| 308 | Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies | 5.0 | 37 | Citations (PDF) |
| 309 | Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes | 1.0 | 22 | Citations (PDF) |
| 310 | Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline | 2.8 | 17 | Citations (PDF) |
| 311 | The Association of Multimorbidity With Preclinical AD Stages and SNAP in Cognitively Unimpaired Persons | 3.5 | 19 | Citations (PDF) |
| 312 | Association of non-exercise physical activity in mid- and late-life with cognitive trajectories and the impact of APOE ε4 genotype status: the Mayo Clinic Study of Aging | 2.7 | 11 | Citations (PDF) |
| 313 | Informant-based hearing difficulties and the risk for mild cognitive impairment and dementia | 1.8 | 21 | Citations (PDF) |
| 314 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework | 17.6 | 269 | Citations (PDF) |
| 315 | Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum | 3.7 | 40 | Citations (PDF) |
| 316 | Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults | 4.9 | 16 | Citations (PDF) |
| 317 | Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers | 5.0 | 52 | Citations (PDF) |
| 318 | Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults | 6.6 | 55 | Citations (PDF) |
| 319 | Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging | 6.6 | 55 | Citations (PDF) |
| 320 | Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging | 1.6 | 3 | Citations (PDF) |
| 321 | Population-Based Evaluation of Lumbar Puncture Opening Pressures | 2.4 | 35 | Citations (PDF) |
| 322 | The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromesBrain, 2019, 142, 3230-3242 | 8.4 | 178 | Citations (PDF) |
| 323 | Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity | 6.0 | 63 | Citations (PDF) |
| 324 | Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volume—Brief Report | 6.0 | 13 | Citations (PDF) |
| 325 | Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degenerationBrain, 2019, 142, 3621-3635 | 8.4 | 62 | Citations (PDF) |
| 326 | Factors Associated With Meningioma Detected in a Population-Based Sample | 3.7 | 8 | Citations (PDF) |
| 327 | The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals | 3.4 | 65 | Citations (PDF) |
| 328 | A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity | 9.2 | 112 | Citations (PDF) |
| 329 | Progressive agrammatic aphasia without apraxia of speech as a distinct syndromeBrain, 2019, 142, 2466-2482 | 8.4 | 49 | Citations (PDF) |
| 330 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia | 16.6 | 302 | Citations (PDF) |
| 331 | Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults | 1.0 | 92 | Citations (PDF) |
| 332 | Plasma and CSF neurofilament light | 1.0 | 254 | Citations (PDF) |
| 333 | White matter hyperintensities: relationship to amyloid and tau burdenBrain, 2019, 142, 2483-2491 | 8.4 | 206 | Citations (PDF) |
| 334 | Investigation of white matter PiB uptake as a marker of white matter integrity | 3.8 | 22 | Citations (PDF) |
| 335 | Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease | 3.3 | 73 | Citations (PDF) |
| 336 | A brief history of “Alzheimer disease” | 1.0 | 86 | Citations (PDF) |
| 337 | Association of <i>MAPT</i> Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology | 17.6 | 55 | Citations (PDF) |
| 338 | The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologiesBrain, 2019, 142, 1134-1147 | 8.4 | 96 | Citations (PDF) |
| 339 | <i>CSF1R</i> mutation presenting as dementia with Lewy bodies | 0.7 | 10 | Citations (PDF) |
| 340 | Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging | 5.2 | 74 | Citations (PDF) |
| 341 | Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging | 3.4 | 10 | Citations (PDF) |
| 342 | Heritability and genetic variance of dementia with Lewy bodies | 5.1 | 38 | Citations (PDF) |
| 343 | Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy | 4.6 | 136 | Citations (PDF) |
| 344 | Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD | 9.2 | 123 | Citations (PDF) |
| 345 | Selective loss of cortical endothelial tight junction proteins during Alzheimer’s disease progressionBrain, 2019, 142, 1077-1092 | 8.4 | 180 | Citations (PDF) |
| 346 | Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing | 25.2 | 2,782 | Citations (PDF) |
| 347 | Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjectsBrain, 2019, 142, 1148-1160 | 8.4 | 87 | Citations (PDF) |
| 348 | IC‐P‐086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING | 0.5 | 0 | Citations (PDF) |
| 349 | Longitudinal Comparison of in Clinic and at Home Administration of the Cogstate Brief Battery and Demonstrated Practice Effects in the Mayo Clinic Study of Aging | 2.8 | 28 | Citations (PDF) |
| 350 | Quantity and quality of mental activities and the risk of incident mild cognitive impairment | 1.0 | 54 | Citations (PDF) |
| 351 | Cerebrospinal fluid dynamics disorders | 1.0 | 30 | Citations (PDF) |
| 352 | IC‐P‐022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGING‐ALZHEIMER'S CONTINUUM | 0.5 | 0 | Citations (PDF) |
| 353 | Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults* | 0.5 | 24 | Citations (PDF) |
| 354 | Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia | 6.6 | 35 | Citations (PDF) |
| 355 | Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains | 9.2 | 82 | Citations (PDF) |
| 356 | Cerebral microbleeds | 1.0 | 69 | Citations (PDF) |
| 357 | Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment | 17.6 | 90 | Citations (PDF) |
| 358 | MRI Outperforms [18F]AV‐1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy | 4.6 | 48 | Citations (PDF) |
| 359 | <sup>18</sup>F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy | 4.6 | 29 | Citations (PDF) |
| 360 | The influence of β-amyloid on [
<sup>18</sup>
F]AV-1451 in semantic variant of primary progressive aphasia | 1.0 | 13 | Citations (PDF) |
| 361 | Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability | 3.3 | 16 | Citations (PDF) |
| 362 | A comprehensive screening of copy number variability in dementia with Lewy bodies | 3.4 | 14 | Citations (PDF) |
| 363 | Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative | 0.5 | 440 | Citations (PDF) |
| 364 | Distinct cytokine profiles in human brains resilient to Alzheimer's pathology | 5.1 | 118 | Citations (PDF) |
| 365 | Predicting Progression to Mild Cognitive Impairment | 6.6 | 37 | Citations (PDF) |
| 366 | Comparison of PC and iPad administrations of the Cogstate Brief Battery in the Mayo Clinic Study of Aging: Assessing cross-modality equivalence of computerized neuropsychological tests | 2.7 | 26 | Citations (PDF) |
| 367 | A Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR | 2.6 | 68 | Citations (PDF) |
| 368 | Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods | 3.3 | 47 | Citations (PDF) |
| 369 | The Cross-sectional and Longitudinal Associations Between IL-6, IL-10, and TNFα and Cognitive Outcomes in the Mayo Clinic Study of Aging | 3.5 | 61 | Citations (PDF) |
| 370 | The association between peripheral total IGF-1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging | 3.4 | 39 | Citations (PDF) |
| 371 | Joint associations of β-amyloidosis and cortical thickness with cognition | 3.4 | 31 | Citations (PDF) |
| 372 | [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation | 3.4 | 31 | Citations (PDF) |
| 373 | White Matter Reference Region in PET Studies of 11C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition | 5.5 | 51 | Citations (PDF) |
| 374 | Frequency of Acute and Subacute Infarcts in a Population-Based Study | 3.7 | 5 | Citations (PDF) |
| 375 | Leisure-Time Physical Activity and the Risk of Incident Dementia: The Mayo Clinic Study of Aging | 2.6 | 39 | Citations (PDF) |
| 376 | The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable | 0.5 | 124 | Citations (PDF) |
| 377 | Elevated medial temporal lobe and pervasive brain tau‐PET signal in normal participants | 2.5 | 26 | Citations (PDF) |
| 378 | [18F]AV‐1451 tau‐PET and primary progressive aphasia | 6.6 | 83 | Citations (PDF) |
| 379 | Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech | 2.9 | 50 | Citations (PDF) |
| 380 | Tau-negative amnestic dementia masquerading as Alzheimer disease dementia | 1.0 | 36 | Citations (PDF) |
| 381 | In vivo
18
F-AV-1451 tau PET signal in
MAPT
mutation carriers varies by expected tau isoforms | 1.0 | 69 | Citations (PDF) |
| 382 | Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly | 1.0 | 73 | Citations (PDF) |
| 383 | Clinicopathological and 123I‐FP‐CIT SPECT correlations in patients with dementia | 3.8 | 12 | Citations (PDF) |
| 384 | Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review | 3.7 | 90 | Citations (PDF) |
| 385 | Practice guideline update summary: Mild cognitive impairment [RETIRED] | 1.0 | 1,924 | Citations (PDF) |
| 386 | Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy | 2.6 | 33 | Citations (PDF) |
| 387 | [18F]AV‐1451 clustering of entorhinal and cortical uptake in Alzheimer's disease | 6.6 | 91 | Citations (PDF) |
| 388 | Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementiaBrain, 2018, 141, 271-287 | 8.4 | 282 | Citations (PDF) |
| 389 | Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging | 3.5 | 42 | Citations (PDF) |
| 390 | Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting | 17.6 | 192 | Citations (PDF) |
| 391 | Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study | 17.9 | 123 | Citations (PDF) |
| 392 | Longitudinal tau PET in ageing and Alzheimer’s diseaseBrain, 2018, 141, 1517-1528 | 8.4 | 419 | Citations (PDF) |
| 393 | Disrupted functional connectivity in primary progressive apraxia of speech | 3.3 | 43 | Citations (PDF) |
| 394 | Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging | 3.7 | 19 | Citations (PDF) |
| 395 | Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia | 17.6 | 191 | Citations (PDF) |
| 396 | FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosisBrain, 2018, 141, 1201-1217 | 8.4 | 108 | Citations (PDF) |
| 397 | Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis | 3.9 | 43 | Citations (PDF) |
| 398 | Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study | 17.9 | 259 | Citations (PDF) |
| 399 | Association Between Microinfarcts and Blood Pressure Trajectories | 17.6 | 16 | Citations (PDF) |
| 400 | Plasma Sphingolipids are Associated With Gait Parameters in the Mayo Clinic Study of Aging | 3.5 | 24 | Citations (PDF) |
| 401 | P2‐491: SUBTLE COGNITIVE DYSFUNCTION ON COGSTATE IS ASSOCIATED WITH BIOMARKER POSITIVE STATUS | 0.5 | 0 | Citations (PDF) |
| 402 | P3‐221: LONGITUDINAL ASSOCIATION BETWEEN PHOSPHATIDYLCHOLINES, NEUROIMAGING MEASURES OF ALZHEIMER'S DISEASE PATHOPHYSIOLOGY, AND COGNITION IN THE MAYO CLINIC STUDY ON AGING | 0.5 | 0 | Citations (PDF) |
| 403 | P3‐238: LONGITUDINAL ASSOCIATIONS OF PLASMA NEUROFILAMENT LEVELS WITH AMYLOID‐PET, FDG‐PET, AND COGNITION AMONG NON‐DEMENTED PARTICIPANTS IN THE MAYO CLINIC STUDY ON AGING | 0.5 | 0 | Citations (PDF) |
| 404 | P2‐273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING | 0.5 | 0 | Citations (PDF) |
| 405 | P4‐078: CONCORDE‐AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE | 0.5 | 0 | Citations (PDF) |
| 406 | IC‐P‐144: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDG‐PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM | 0.5 | 0 | Citations (PDF) |
| 407 | F2‐02‐01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD | 0.5 | 0 | Citations (PDF) |
| 408 | O2‐13‐01: INCIDENCE OF CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING | 0.5 | 0 | Citations (PDF) |
| 409 | IC‐P‐083: DIAGNOSTIC UTILITY OF [18F]AV‐1451 PET, FDG‐PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA | 0.5 | 0 | Citations (PDF) |
| 410 | IC‐P‐019: LONGITUDINAL ACCUMULATION OF β‐AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION | 0.5 | 0 | Citations (PDF) |
| 411 | Amyloid- and tau-PET imaging in a familial prion kindred | 2.8 | 5 | Citations (PDF) |
| 412 | P2‐334: THE INFLUENCE OF BETA‐AMYLOID ON THE PROGRESSION OF PROGRESSIVE APRAXIA OF SPEECH | 0.5 | 1 | Citations (PDF) |
| 413 | FTS3‐01‐03: U.S. PERSPECTIVE ON CLINICAL AMYLOID IMAGING | 0.5 | 0 | Citations (PDF) |
| 414 | P3‐597: MEDIAL TEMPORAL LOBE NEURODEGENERATION OBSERVED IN WOMEN WHO UNDERWENT BILATERAL OOPHORECTOMY BEFORE THE ONSET OF MENOPAUSE | 0.5 | 0 | Citations (PDF) |
| 415 | P3‐424: LONGITUDINAL ACCUMULATION OF β‐AMYLOID ON PET IN DEMENTIA WITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION | 0.5 | 0 | Citations (PDF) |
| 416 | P3‐202: TDP‐43 IN ATYPICAL ALZHEIMER'S DISEASE DEMENTIA | 0.5 | 0 | Citations (PDF) |
| 417 | Effect of Cognitive Status on the Receipt of Procedures Requiring Anesthesia and Critical Care Admissions in Older Adults | 3.7 | 7 | Citations (PDF) |
| 418 | Risk Factors for Persistent Cognitive Impairment After Critical Illness, Nested Case-Control Study | 0.5 | 31 | Citations (PDF) |
| 419 | Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia | 2.9 | 13 | Citations (PDF) |
| 420 | A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriersBrain, 2018, 141, 2895-2907 | 8.4 | 52 | Citations (PDF) |
| 421 | Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging | 6.6 | 65 | Citations (PDF) |
| 422 | Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43 | 17.6 | 80 | Citations (PDF) |
| 423 | P2‐407: COGNITIVE RESILIENCE IN 80+: PREDICTORS AND IMAGING CORRELATES OF COGNITION | 0.5 | 0 | Citations (PDF) |
| 424 | ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans | 14.1 | 94 | Citations (PDF) |
| 425 | Statins and Brain Health: Alzheimer’s Disease and Cerebrovascular Disease Biomarkers in Older Adults | 2.6 | 27 | Citations (PDF) |
| 426 | Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech | 3.5 | 12 | Citations (PDF) |
| 427 | 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus | 3.3 | 51 | Citations (PDF) |
| 428 | Association between exposure to anaesthesia and surgery and long-term cognitive trajectories in older adults: report from the Mayo Clinic Study of Aging | 4.9 | 67 | Citations (PDF) |
| 429 | Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers | 2.6 | 44 | Citations (PDF) |
| 430 | Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET | 3.3 | 39 | Citations (PDF) |
| 431 | Sex-specific genetic predictors of Alzheimer’s disease biomarkers | 9.2 | 114 | Citations (PDF) |
| 432 | Subjective cognitive decline and risk of MCI | 1.0 | 265 | Citations (PDF) |
| 433 | Prosodic and phonetic subtypes of primary progressive apraxia of speech | 1.8 | 144 | Citations (PDF) |
| 434 | TDP-43 and Alzheimer’s Disease Pathologic Subtype in Non-Amnestic Alzheimer’s Disease Dementia | 2.6 | 24 | Citations (PDF) |
| 435 | Non-right handed primary progressive apraxia of speech | 2.1 | 4 | Citations (PDF) |
| 436 | Mild Cognitive Impairment in Geriatrics | 3.3 | 144 | Citations (PDF) |
| 437 | <i>APOE</i>
ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology | 1.0 | 191 | Citations (PDF) |
| 438 | Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population‐based Mayo Clinic Study of Aging | 2.2 | 34 | Citations (PDF) |
| 439 | Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies | 3.4 | 40 | Citations (PDF) |
| 440 | Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives | 10.6 | 436 | Citations (PDF) |
| 441 | Comparison of Gait Parameters for Predicting Cognitive Decline: The Mayo Clinic Study of Aging | 2.6 | 107 | Citations (PDF) |
| 442 | Duration and Pathologic Correlates of Lewy Body Disease | 17.6 | 60 | Citations (PDF) |
| 443 | ABCA7
loss-of-function variants, expression, and neurologic disease risk | 2.8 | 35 | Citations (PDF) |
| 444 | A robust biomarker of large‐scale network failure in Alzheimer's disease | 2.5 | 32 | Citations (PDF) |
| 445 | Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART) | 9.2 | 155 | Citations (PDF) |
| 446 | Association Between Mentally Stimulating Activities in Late Life and the Outcome of Incident Mild Cognitive Impairment, With an Analysis of the APOE ε4 Genotype | 17.6 | 93 | Citations (PDF) |
| 447 | Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers | 9.2 | 241 | Citations (PDF) |
| 448 | Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals | 17.6 | 125 | Citations (PDF) |
| 449 | Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults | 17.6 | 121 | Citations (PDF) |
| 450 | Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study | 17.9 | 293 | Citations (PDF) |
| 451 | In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers | 9.2 | 90 | Citations (PDF) |
| 452 | Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population‐based sample | 2.5 | 7 | Citations (PDF) |
| 453 | Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals | 6.6 | 60 | Citations (PDF) |
| 454 | White-matter integrity on DTI and the pathologic staging of Alzheimer's disease | 3.4 | 192 | Citations (PDF) |
| 455 | Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons | 16.6 | 422 | Citations (PDF) |
| 456 | Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials | 0.5 | 258 | Citations (PDF) |
| 457 | Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individualsBrain, 2017, 140, 1499-1512 | 8.4 | 108 | Citations (PDF) |
| 458 | Randomized controlled trials in mild cognitive impairment | 1.0 | 39 | Citations (PDF) |
| 459 | Brain tau deposition linked to systemic causes of death in normal elderly | 3.4 | 3 | Citations (PDF) |
| 460 | Tau‐PET uptake: Regional variation in average SUVR and impact of amyloid deposition | 2.5 | 100 | Citations (PDF) |
| 461 | The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement | 0.5 | 418 | Citations (PDF) |
| 462 | Prevalence and Natural History of Superficial Siderosis | 6.0 | 46 | Citations (PDF) |
| 463 | Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease | 3.4 | 80 | Citations (PDF) |
| 464 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum | 2.9 | 211 | Citations (PDF) |
| 465 | Age, vascular health, and Alzheimer disease biomarkers in an elderly sample | 6.6 | 166 | Citations (PDF) |
| 466 | Uptake of AV-1451 in meningiomas | 2.0 | 9 | Citations (PDF) |
| 467 | Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers | 1.0 | 15 | Citations (PDF) |
| 468 | Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study | 17.9 | 212 | Citations (PDF) |
| 469 | Nursing Home Use Across The Spectrum of Cognitive Decline: Merging Mayo Clinic Study of Aging With CMS MDS Assessments | 2.9 | 2 | Citations (PDF) |
| 470 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease | 25.2 | 961 | Citations (PDF) |
| 471 | Neurocognition in individuals with incidentally-identified meningioma | 2.5 | 28 | Citations (PDF) |
| 472 | Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB‐PET Study | 2.2 | 36 | Citations (PDF) |
| 473 | Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging | 2.6 | 25 | Citations (PDF) |
| 474 | Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging | 17.6 | 183 | Citations (PDF) |
| 475 | Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease | 1.7 | 33 | Citations (PDF) |
| 476 | Abnormal expression of homeobox genes and transthyretin in
C9ORF72
expansion carriers | 2.8 | 16 | Citations (PDF) |
| 477 | Derivation and validation of the automated search algorithms to identify cognitive impairment and dementia in electronic health records | 2.3 | 50 | Citations (PDF) |
| 478 | AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies | 6.6 | 173 | Citations (PDF) |
| 479 | Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status | 2.7 | 59 | Citations (PDF) |
| 480 | [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy | 4.6 | 160 | Citations (PDF) |
| 481 | Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults | 1.7 | 95 | Citations (PDF) |
| 482 | FTDP‐17 with Pick body‐like inclusions associated with a novel tau mutation, p.E372G | 5.0 | 13 | Citations (PDF) |
| 483 | Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging | 2.3 | 20 | Citations (PDF) |
| 484 | Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies | 3.4 | 12 | Citations (PDF) |
| 485 | Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE | 4.4 | 73 | Citations (PDF) |
| 486 | Tracking the development of agrammatic aphasia: A tensor-based morphometry study | 2.9 | 25 | Citations (PDF) |
| 487 | Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging | 2.9 | 52 | Citations (PDF) |
| 488 | Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP‐17) due to microtubule‐associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy | 3.1 | 63 | Citations (PDF) |
| 489 | [P1–393]: PATTERN OF HYPOPERFUSION ON ASL OVERLAPS WITH HYPOMETABOLISM ON FDG‐PET IN DEMENTIA WITH LEWY BODIES | 0.5 | 0 | Citations (PDF) |
| 490 | [P2–415]: THE MAYO CLINIC ADULT LIFESPAN TEMPLATE: BETTER QUANTIFICATION ACROSS THE LIFESPAN | 0.5 | 43 | Citations (PDF) |
| 491 | [IC‐P‐204]: SUBJECT‐LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAU‐PET, AMYLOID‐PET, MRI AND FDG‐PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER's DISEASE | 0.5 | 0 | Citations (PDF) |
| 492 | [F4–03–04]: INTERVENTIONS FOR PREVENTING COGNITIVE DECLINE AND DEMENTIA: RECOMMENDATIONS FROM A NATIONAL ACADEMIES OF SCIENCES, ENGINEERING, AND MEDICINE STUDY | 0.5 | 0 | Citations (PDF) |
| 493 | Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer’s diseaseBrain, 2017, 140, 3301-3316 | 8.4 | 24 | Citations (PDF) |
| 494 | 1
H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults | 1.0 | 27 | Citations (PDF) |
| 495 | Decreased Expression of Sulfatase 2 in the Brains of Alzheimer’s Disease Patients: Implications for Regulation of Neuronal Cell Signaling | 2.3 | 18 | Citations (PDF) |
| 496 | Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors | 2.5 | 12 | Citations (PDF) |
| 497 | Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals | 3.3 | 43 | Citations (PDF) |
| 498 | Advanced 1H-MRS detects decreased glutamate levels in amnestic MCI (P4.093) | 1.0 | 0 | Citations (PDF) |
| 499 | Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer’s Disease: A Diffusion Tensor Imaging Study | 2.6 | 31 | Citations (PDF) |
| 500 | FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging | 2.6 | 42 | Citations (PDF) |
| 501 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers | 1.0 | 1,671 | Citations (PDF) |
| 502 | MAPT haplotype diversity in multiple system atrophy | 2.6 | 29 | Citations (PDF) |
| 503 | Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases | 5.7 | 467 | Citations (PDF) |
| 504 | First PET Imaging Studies With
63
Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease | 4.2 | 26 | Citations (PDF) |
| 505 | Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging | 2.6 | 78 | Citations (PDF) |
| 506 | Mild Cognitive Impairment and Risk of Critical Illness* | 0.5 | 30 | Citations (PDF) |
| 507 | FTS3‐03‐01: The U.S. National Alzheimer’s Plan: Five Years Later | 0.5 | 0 | Citations (PDF) |
| 508 | RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies | 3.4 | 21 | Citations (PDF) |
| 509 | Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease | 9.2 | 99 | Citations (PDF) |
| 510 | Multimorbidity and neuroimaging biomarkers among cognitively normal persons | 1.0 | 42 | Citations (PDF) |
| 511 | Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology | 1.0 | 47 | Citations (PDF) |
| 512 | Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults | 17.6 | 312 | Citations (PDF) |
| 513 | Network-driven plasma proteomics expose molecular changes in the Alzheimer’s brain | 14.1 | 43 | Citations (PDF) |
| 514 | Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals | 3.7 | 15 | Citations (PDF) |
| 515 | TYROBP genetic variants in early-onset Alzheimer's disease | 3.4 | 80 | Citations (PDF) |
| 516 | An autoradiographic evaluation of AV-1451 Tau PET in dementia | 5.0 | 441 | Citations (PDF) |
| 517 | Prosaposin is a regulator of progranulin levels and oligomerization | 13.7 | 84 | Citations (PDF) |
| 518 | LRRK2 variation and dementia with Lewy bodies | 2.6 | 42 | Citations (PDF) |
| 519 | A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity | 3.3 | 372 | Citations (PDF) |
| 520 | Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodiesBrain, 2016, 139, 2740-2750 | 8.4 | 80 | Citations (PDF) |
| 521 | Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia | 1.0 | 29 | Citations (PDF) |
| 522 | Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum | 3.4 | 24 | Citations (PDF) |
| 523 | Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease | 1.7 | 23 | Citations (PDF) |
| 524 | Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment | 1.0 | 54 | Citations (PDF) |
| 525 | CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia | 13.7 | 203 | Citations (PDF) |
| 526 | Timing of Physical Activity, Apolipoprotein E
ε
4 Genotype, and Risk of Incident Mild Cognitive Impairment | 2.9 | 32 | Citations (PDF) |
| 527 | MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies | 0.5 | 40 | Citations (PDF) |
| 528 | Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry | 4.6 | 40 | Citations (PDF) |
| 529 | Association of Mild Cognitive Impairment With Exposure to General Anesthesia for Surgical and Nonsurgical Procedures | 3.7 | 60 | Citations (PDF) |
| 530 | Updated TDP-43 in Alzheimer’s disease staging scheme | 9.2 | 318 | Citations (PDF) |
| 531 | Suspected non-Alzheimer disease pathophysiology — concept and controversy | 28.6 | 276 | Citations (PDF) |
| 532 | Cascading network failure across the Alzheimer’s disease spectrumBrain, 2016, 139, 547-562 | 8.4 | 500 | Citations (PDF) |
| 533 | Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study | 17.9 | 114 | Citations (PDF) |
| 534 | Effect of intellectual enrichment on AD biomarker trajectories | 1.0 | 77 | Citations (PDF) |
| 535 | Decline in Weight and Incident Mild Cognitive Impairment | 17.6 | 120 | Citations (PDF) |
| 536 | Plasma sphingolipid changes with autopsy‐confirmed Lewy body or Alzheimer's pathology | 2.5 | 48 | Citations (PDF) |
| 537 | Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia | 17.6 | 367 | Citations (PDF) |
| 538 | Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community | 17.6 | 185 | Citations (PDF) |
| 539 | Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism | 9.2 | 73 | Citations (PDF) |
| 540 | Age and education corrected older adult normative data for a short form version of the Financial Capacity Instrument. | 1.5 | 40 | Citations (PDF) |
| 541 | Low neural exosomal levels of cellular survival factors in Alzheimer's disease | 3.8 | 194 | Citations (PDF) |
| 542 | Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies | 2.6 | 396 | Citations (PDF) |
| 543 | Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer’s pathophysiology and susceptibility | 14.1 | 19 | Citations (PDF) |
| 544 | Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging | 2.6 | 26 | Citations (PDF) |
| 545 | Mortality in Mild Cognitive Impairment Varies by Subtype, Sex, and Lifestyle Factors: The Mayo Clinic Study of Aging | 2.6 | 56 | Citations (PDF) |
| 546 | DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients | 3.5 | 23 | Citations (PDF) |
| 547 | Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele | 4.0 | 6 | Citations (PDF) |
| 548 | Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States | 17.6 | 47 | Citations (PDF) |
| 549 | Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease | 1.0 | 435 | Citations (PDF) |
| 550 | Mitochondrial targeting sequence variants of the
CHCHD2
gene are a risk for Lewy body disorders | 1.0 | 64 | Citations (PDF) |
| 551 | F5‐04‐04: Scd in a population‐based sample: Progression to MCI 2015, 11, | | 0 | Citations (PDF) |
| 552 | Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type | 2.6 | 20 | Citations (PDF) |
| 553 | Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia | 3.4 | 99 | Citations (PDF) |
| 554 | Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images | 3.5 | 117 | Citations (PDF) |
| 555 | 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception | 0.5 | 306 | Citations (PDF) |
| 556 | Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrumBrain, 2015, 138, 1370-1381 | 8.4 | 310 | Citations (PDF) |
| 557 | Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 | 0.5 | 225 | Citations (PDF) |
| 558 | The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans | 0.5 | 95 | Citations (PDF) |
| 559 | Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans | 0.5 | 124 | Citations (PDF) |
| 560 | Sample size calculations for clinical trials targeting tauopathies: a new potential disease target | 3.4 | 13 | Citations (PDF) |
| 561 | Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease | 2.6 | 31 | Citations (PDF) |
| 562 | Neuropsychiatric symptoms,
APOE
ε4, and the risk of incident dementia | 1.0 | 125 | Citations (PDF) |
| 563 | Risk and protective factors for cognitive impairment in persons aged 85 years and older | 1.0 | 76 | Citations (PDF) |
| 564 | Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderlyBrain, 2015, 138, 761-771 | 8.4 | 261 | Citations (PDF) |
| 565 | Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span | 17.6 | 358 | Citations (PDF) |
| 566 | Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease | 9.2 | 305 | Citations (PDF) |
| 567 | Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging | 1.0 | 118 | Citations (PDF) |
| 568 | White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging | 3.4 | 47 | Citations (PDF) |
| 569 | Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease | 4.4 | 41 | Citations (PDF) |
| 570 | Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findingsBrain, 2015, 138, 3747-3759 | 8.4 | 228 | Citations (PDF) |
| 571 | Multimorbidity and Risk of Mild Cognitive Impairment | 2.9 | 184 | Citations (PDF) |
| 572 | Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment | 17.6 | 23 | Citations (PDF) |
| 573 | Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72 | 9.2 | 116 | Citations (PDF) |
| 574 | Spectrum of cognition short of dementia | 1.0 | 81 | Citations (PDF) |
| 575 | Late-onset Alzheimer disease risk variants mark brain regulatory loci | 2.8 | 73 | Citations (PDF) |
| 576 | Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers | 9.2 | 100 | Citations (PDF) |
| 577 | Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies | 1.0 | 33 | Citations (PDF) |
| 578 | GWAS of longitudinal amyloid accumulation on18F-florbetapir PET in Alzheimer’s disease implicates microglial activation geneIL1RAPBrain, 2015, 138, 3076-3088 | 8.4 | 139 | Citations (PDF) |
| 579 | Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies | 3.4 | 141 | Citations (PDF) |
| 580 | Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease | 3.4 | 91 | Citations (PDF) |
| 581 | MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease | 2.2 | 24 | Citations (PDF) |
| 582 | At the interface of sensory and motor dysfunctions and Alzheimer's disease | 0.5 | 545 | Citations (PDF) |
| 583 | Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test | 6.6 | 55 | Citations (PDF) |
| 584 | Antemortem MRI findings associated with microinfarcts at autopsy | 1.0 | 47 | Citations (PDF) |
| 585 | Association of hypometabolism and amyloid levels in aging, normal subjects | 1.0 | 80 | Citations (PDF) |
| 586 | The GGGGCC Repeat Expansion inC9ORF72in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome | 0.7 | 15 | Citations (PDF) |
| 587 | Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy | 3.7 | 145 | Citations (PDF) |
| 588 | White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia | 17.6 | 77 | Citations (PDF) |
| 589 | Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene | 14.1 | 76 | Citations (PDF) |
| 590 | Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels | 6.6 | 140 | Citations (PDF) |
| 591 | Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease | 17.6 | 186 | Citations (PDF) |
| 592 | Association of Lifetime Intellectual Enrichment With Cognitive Decline in the Older Population | 17.6 | 196 | Citations (PDF) |
| 593 | A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment | 17.6 | 130 | Citations (PDF) |
| 594 | Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons | 17.6 | 61 | Citations (PDF) |
| 595 | Dementia with Lewy bodies | 1.0 | 166 | Citations (PDF) |
| 596 | Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies | 3.4 | 32 | Citations (PDF) |
| 597 | TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia | 9.2 | 154 | Citations (PDF) |
| 598 | Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers | 3.4 | 82 | Citations (PDF) |
| 599 | Short and long telomeres increase risk of amnestic mild cognitive impairment | 4.7 | 39 | Citations (PDF) |
| 600 | Progranulin protein levels are differently regulated in plasma and CSF | 1.0 | 84 | Citations (PDF) |
| 601 | Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective | 3.7 | 330 | Citations (PDF) |
| 602 | Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation | 5.5 | 148 | Citations (PDF) |
| 603 | Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study | 17.9 | 340 | Citations (PDF) |
| 604 | TDP-43 is a key player in the clinical features associated with Alzheimer’s disease | 9.2 | 435 | Citations (PDF) |
| 605 | TDP-43 in Alzheimer’s disease is not associated with clinical FTLD or Parkinsonism | 3.4 | 22 | Citations (PDF) |
| 606 | Frontotemporal dementia and its subtypes: a genome-wide association study | 17.9 | 377 | Citations (PDF) |
| 607 | Association of plasma and cortical amyloid beta is modulated by APOE ε4 status | 0.5 | 45 | Citations (PDF) |
| 608 | Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s diseaseBrain, 2014, 137, 1533-1549 | 8.4 | 112 | Citations (PDF) |
| 609 | 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons | 3.4 | 121 | Citations (PDF) |
| 610 | Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics | 4.4 | 170 | Citations (PDF) |
| 611 | Genome-wide association interaction analysis for Alzheimer's disease | 3.4 | 63 | Citations (PDF) |
| 612 | Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative | 0.5 | 63 | Citations (PDF) |
| 613 | Association of Mediterranean Diet with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis | 2.6 | 607 | Citations (PDF) |
| 614 | Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration | 1.0 | 124 | Citations (PDF) |
| 615 | FASTKD2 is associated with memory and hippocampal structure in older adults | 7.8 | 34 | Citations (PDF) |
| 616 | TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease | 14.1 | 378 | Citations (PDF) |
| 617 | The alien limb phenomenon | 3.4 | 88 | Citations (PDF) |
| 618 | Chronic Obstructive Pulmonary Disease and Association With Mild Cognitive Impairment: The Mayo Clinic Study of Aging | 3.7 | 60 | Citations (PDF) |
| 619 | Emerging Biomarkers in Cognition | 3.3 | 14 | Citations (PDF) |
| 620 | Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study | 17.9 | 257 | Citations (PDF) |
| 621 | Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | 17.9 | 4,020 | Citations (PDF) |
| 622 | Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates | 3.4 | 59 | Citations (PDF) |
| 623 | Neurocognitive speed associates with frontotemporal lobar degeneration TDP-43 subtypes | 1.6 | 1 | Citations (PDF) |
| 624 | The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception | 0.5 | 643 | Citations (PDF) |
| 625 | The Effect of Subsyndromal Symptoms of Depression and White Matter Lesions on Disability for Individuals with Mild Cognitive Impairment | 1.7 | 46 | Citations (PDF) |
| 626 | Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? | 3.3 | 46 | Citations (PDF) |
| 627 | Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer’s disease presenting as logopenic progressive aphasia | 1.8 | 56 | Citations (PDF) |
| 628 | Brain β-amyloid load approaches a plateau | 1.0 | 384 | Citations (PDF) |
| 629 | Mild cognitive impairment due to Alzheimer disease in the community | 6.6 | 241 | Citations (PDF) |
| 630 | Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation | 9.2 | 56 | Citations (PDF) |
| 631 | Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI | 1.0 | 48 | Citations (PDF) |
| 632 | Clinical and electrophysiologic variability in amyotrophic lateral sclerosis within a kindred harboring the
C9ORF72
repeat expansion | 2.5 | 7 | Citations (PDF) |
| 633 | Occupational Differences Between Alzheimer’s and Aphasic Dementias | 2.0 | 9 | Citations (PDF) |
| 634 | Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging | 2.7 | 145 | Citations (PDF) |
| 635 | Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity | 1.0 | 199 | Citations (PDF) |
| 636 | Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology | 3.5 | 59 | Citations (PDF) |
| 637 | Caloric Intake, Aging, and Mild Cognitive Impairment: A Population-Based Study | 2.6 | 35 | Citations (PDF) |
| 638 | Subtle gait changes in patients with REM sleep behavior disorder | 4.6 | 70 | Citations (PDF) |
| 639 | LRRTM3 Interacts with APP and BACE1 and Has Variants Associating with Late-Onset Alzheimer’s Disease (LOAD) | 2.3 | 16 | Citations (PDF) |
| 640 | The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) | 4.0 | 133 | Citations (PDF) |
| 641 | Staging TDP-43 pathology in Alzheimer’s disease | 9.2 | 339 | Citations (PDF) |
| 642 | APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study | 7.8 | 193 | Citations (PDF) |
| 643 | FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type | 2.3 | 117 | Citations (PDF) |
| 644 | Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics | 2.3 | 408 | Citations (PDF) |
| 645 | Linking Protective GAB2 Variants, Increased Cortical GAB2 Expression and Decreased Alzheimer’s Disease Pathology | 2.3 | 13 | Citations (PDF) |
| 646 | Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel | 2.3 | 53 | Citations (PDF) |
| 647 | Nimodipine in the Treatment of Probable Alzheimerʼs Disease | 2.1 | 22 | Citations (PDF) |
| 648 | Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants | 3.2 | 236 | Citations (PDF) |
| 649 | Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadicsBrain, 2012, 135, 794-806 | 8.4 | 381 | Citations (PDF) |
| 650 | Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases | 2.9 | 222 | Citations (PDF) |
| 651 | Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72Brain, 2012, 135, 765-783 | 8.4 | 338 | Citations (PDF) |
| 652 | APOE
modifies the association between Aβ load and cognition in cognitively normal older adults | 1.0 | 158 | Citations (PDF) |
| 653 | Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia | 2.6 | 159 | Citations (PDF) |
| 654 | Considerations in the Design of Clinical Trials for Cognitive Aging | 3.5 | 14 | Citations (PDF) |
| 655 | Amyloid deposition, hypometabolism, and longitudinal cognitive decline | 6.6 | 662 | Citations (PDF) |
| 656 | Effect of lifestyle activities on alzheimer disease biomarkers and cognition | 6.6 | 163 | Citations (PDF) |
| 657 | The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception | 0.5 | 460 | Citations (PDF) |
| 658 | ApoE and Quality of Life in Nonagenarians | 2.4 | 3 | Citations (PDF) |
| 659 | Association and heterogeneity at the GAPDH locus in Alzheimer's disease | 3.4 | 18 | Citations (PDF) |
| 660 | Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies | 3.4 | 71 | Citations (PDF) |
| 661 | Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance | 3.4 | 370 | Citations (PDF) |
| 662 | Multimodality imaging characteristics of dementia with Lewy bodies | 3.4 | 169 | Citations (PDF) |
| 663 | Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study | 17.9 | 419 | Citations (PDF) |
| 664 | Limb immobilization and corticobasal syndrome | 2.6 | 4 | Citations (PDF) |
| 665 | Computer Activities, Physical Exercise, Aging, and Mild Cognitive Impairment: A Population-Based Study | 3.7 | 66 | Citations (PDF) |
| 666 | Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks | 2.1 | 59 | Citations (PDF) |
| 667 | Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications | 14.1 | 91 | Citations (PDF) |
| 668 | Non-Stationarity in the “Resting Brain’s” Modular Architecture | 2.3 | 417 | Citations (PDF) |
| 669 | Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodiesBrain, 2012, 135, 2470-2477 | 8.4 | 75 | Citations (PDF) |
| 670 | Voxel‐based morphometry in patients with obsessive‐compulsive behaviors in behavioral variant frontotemporal dementia | 3.5 | 52 | Citations (PDF) |
| 671 | Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: A population‐based study | 6.6 | 188 | Citations (PDF) |
| 672 | Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults | 1.0 | 71 | Citations (PDF) |
| 673 | Mild Cognitive Impairment | 34.6 | 1,204 | Citations (PDF) |
| 674 | Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND | 4.4 | 99 | Citations (PDF) |
| 675 | Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD | 4.4 | 27 | Citations (PDF) |
| 676 | Normative spatiotemporal gait parameters in older adults | 1.3 | 692 | Citations (PDF) |
| 677 | Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy | 2.6 | 26 | Citations (PDF) |
| 678 | Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis | 3.4 | 120 | Citations (PDF) |
| 679 | Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study | 3.4 | 104 | Citations (PDF) |
| 680 | Association of common KIBRA variants with episodic memory and AD risk | 3.4 | 41 | Citations (PDF) |
| 681 | Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort | 1.7 | 265 | Citations (PDF) |
| 682 | Prevention of Dementia | 2.1 | 42 | Citations (PDF) |
| 683 | Ataxin-2 repeat-length variation and neurodegeneration | 2.9 | 164 | Citations (PDF) |
| 684 | Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid 2011, 7, 133-141 | | 87 | Citations (PDF) |
| 685 | Investigating Statistical Epistasis in Complex Disorders | 2.6 | 11 | Citations (PDF) |
| 686 | Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease | 25.2 | 1,840 | Citations (PDF) |
| 687 | Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | 25.2 | 1,902 | Citations (PDF) |
| 688 | Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study | 17.9 | 892 | Citations (PDF) |
| 689 | Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS | 11.0 | 4,705 | Citations (PDF) |
| 690 | Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia | 2.4 | 63 | Citations (PDF) |
| 691 | Replication of EPHA1 and CD33 associations with late-onset Alzheimer's disease: a multi-centre case-control study | 14.1 | 77 | Citations (PDF) |
| 692 | Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognitionBrain, 2011, 134, 1479-1492 | 8.4 | 130 | Citations (PDF) |
| 693 | Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions | 6.2 | 67 | Citations (PDF) |
| 694 | Replication of
BIN1
Association with Alzheimer's Disease and Evaluation of Genetic Interactions | 2.6 | 62 | Citations (PDF) |
| 695 | Predicting functional decline in behavioural variant frontotemporal dementiaBrain, 2011, 134, 432-448 | 8.4 | 51 | Citations (PDF) |
| 696 | Age-related changes in the default mode network are more advanced in Alzheimer disease | 1.0 | 361 | Citations (PDF) |
| 697 | Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids | 25.2 | 507 | Citations (PDF) |
| 698 | Functional characterization of three single‐nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA–protein interactions | 1.5 | 40 | Citations (PDF) |
| 699 | Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease | 6.6 | 174 | Citations (PDF) |
| 700 | Polyunsaturated Fatty Acids and Reduced Odds of MCI: The Mayo Clinic Study of Aging | 2.6 | 53 | Citations (PDF) |
| 701 | FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration | 9.2 | 238 | Citations (PDF) |
| 702 | Clinical trials for early (pre-dementia) Alzheimer's disease: A case for mild cognitive impairment | 3.1 | 11 | Citations (PDF) |
| 703 | Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | 17.9 | 4,341 | Citations (PDF) |
| 704 | Alzheimer's disease: progress in prediction | 17.9 | 60 | Citations (PDF) |
| 705 | Anatomical differences between CBS‐corticobasal degeneration and CBS‐Alzheimer's disease | 4.6 | 82 | Citations (PDF) |
| 706 | Prevalence of mild cognitive impairment is higher in men | 1.0 | 684 | Citations (PDF) |
| 707 | Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aß, and Alzheimer's Disease | 2.3 | 50 | Citations (PDF) |
| 708 | Robust and Expanded Norms for the Dementia Rating Scale | 0.4 | 72 | Citations (PDF) |
| 709 | Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological studyBrain, 2010, 133, 540-556 | 8.4 | 204 | Citations (PDF) |
| 710 | MRS in presymptomatic
MAPT
mutation carriers | 1.0 | 47 | Citations (PDF) |
| 711 | Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia | 1.0 | 246 | Citations (PDF) |
| 712 | Utility of the drs for predicting problems in day-to-day functioning | 2.7 | 28 | Citations (PDF) |
| 713 | Coronary heart disease is associated with non-amnestic mild cognitive impairment | 3.4 | 118 | Citations (PDF) |
| 714 | 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects | 3.4 | 137 | Citations (PDF) |
| 715 | Alzheimer's Disease Neuroimaging Initiative (ADNI) | 1.0 | 2,209 | Citations (PDF) |
| 716 | Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans | 0.5 | 478 | Citations (PDF) |
| 717 | IC‐03‐01: Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center 2010, 6, | | 2 | Citations (PDF) |
| 718 | Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease | 2.9 | 58 | Citations (PDF) |
| 719 | Age, family history, and memory and future risk for cognitive impairment | 1.0 | 11 | Citations (PDF) |
| 720 | Mild Cognitive Impairment | 6.8 | 1,310 | Citations (PDF) |
| 721 | Imaging and Biomarkers in Early Alzheimer's Disease and Mild Cognitive Impairment | 4.7 | 51 | Citations (PDF) |
| 722 | Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease | 25.2 | 288 | Citations (PDF) |
| 723 | Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis studyBrain, 2009, 132, 2932-2946 | 8.4 | 309 | Citations (PDF) |
| 724 | Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease | 3.4 | 601 | Citations (PDF) |
| 725 | Recurrent seizures in patients with dementia: Frequency, seizure types, and treatment outcome | 1.8 | 159 | Citations (PDF) |
| 726 | Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease | 9.2 | 131 | Citations (PDF) |
| 727 | Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia | 3.4 | 94 | Citations (PDF) |
| 728 | β‐amyloid burden is not associated with rates of brain atrophy | 6.6 | 206 | Citations (PDF) |
| 729 | Age and apoE associations with complex pathologic features in Alzheimer's disease | 2.1 | 30 | Citations (PDF) |
| 730 | Voxel-based morphometry in autopsy proven PSP and CBD | 3.4 | 240 | Citations (PDF) |
| 731 | Argyrophilic grains: A distinct disease or an additive pathology? | 3.4 | 86 | Citations (PDF) |
| 732 | Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy | 2.6 | 28 | Citations (PDF) |
| 733 | Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies | 4.4 | 414 | Citations (PDF) |
| 734 | Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease | 4.4 | 58 | Citations (PDF) |
| 735 | Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage | 4.4 | 160 | Citations (PDF) |
| 736 | Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases | 1.8 | 145 | Citations (PDF) |
| 737 | Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis | 3.2 | 424 | Citations (PDF) |
| 738 | The anatomic correlate of prosopagnosia in semantic dementia | 1.0 | 113 | Citations (PDF) |
| 739 | 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain, 2008, 131, 665-680 | 8.4 | 875 | Citations (PDF) |
| 740 | MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment | 1.0 | 348 | Citations (PDF) |
| 741 | Atrophy rates accelerate in amnestic mild cognitive impairment | 1.0 | 173 | Citations (PDF) |
| 742 | Mild Cognitive Impairment: Current Research and Clinical Implications | 1.7 | 182 | Citations (PDF) |
| 743 | Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease | 2.9 | 55 | Citations (PDF) |
| 744 | Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations | 1.8 | 190 | Citations (PDF) |
| 745 | Imaging correlates of posterior cortical atrophy | 3.4 | 192 | Citations (PDF) |
| 746 | Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease | 3.4 | 197 | Citations (PDF) |
| 747 | The current status of mild cognitive impairment—what do we tell our patients? | 6.0 | 14 | Citations (PDF) |
| 748 | 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's diseaseBrain, 2007, 130, 1777-1786 | 8.4 | 575 | Citations (PDF) |
| 749 | Mayo's Older Americans Normative Studies: Visual Form Discrimination and copy trial of the Rey–Osterrieth Complex Figure | 1.0 | 56 | Citations (PDF) |
| 750 | Alzheimer's Disease and Mild Cognitive Impairment | 2.6 | 291 | Citations (PDF) |
| 751 | The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease | 25.2 | 1,128 | Citations (PDF) |
| 752 | Neuropsychological Differentiation of Dementia with Lewy Bodies from Normal Aging and Alzheimer's Disease | 2.7 | 197 | Citations (PDF) |
| 753 | Mild Cognitive Impairment Should Be Considered for DSM-V | 2.6 | 62 | Citations (PDF) |
| 754 | Neuropathologic Features of Amnestic Mild Cognitive Impairment | 6.8 | 585 | Citations (PDF) |
| 755 | Mortality in amnestic mild cognitive impairment | 1.0 | 57 | Citations (PDF) |
| 756 | Conversion | 1.0 | 16 | Citations (PDF) |
| 757 | Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease | 1.0 | 95 | Citations (PDF) |
| 758 | Mild Cognitive Impairment: Where Are We? | 1.3 | 25 | Citations (PDF) |
| 759 | Antemortem diagnosis of frontotemporal lobar degeneration | 6.6 | 188 | Citations (PDF) |
| 760 | Mild Cognitive Impairment: Is it Alzheimer's disease or Not? | 2.6 | 44 | Citations (PDF) |
| 761 | Mild Cognitive Impairment as a Clinical Entity and Treatment Target | 6.8 | 848 | Citations (PDF) |
| 762 | Mayo's Older African American Normative Studies: Norms for the Mattis Dementia Rating Scale | 2.7 | 42 | Citations (PDF) |
| 763 | A Brief Report on WAIS-R Normative Data Collection in Mayo's Older African Americans Normative Studies | 2.7 | 20 | Citations (PDF) |
| 764 | Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI) 2005, 1, 55-66 | | 1,109 | Citations (PDF) |
| 765 | Commentary on “Diagnosis of Alzheimer's disease: Two decades of progress” 2005, 1, 122-123 | | 0 | Citations (PDF) |
| 766 | Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease | 4.4 | 181 | Citations (PDF) |
| 767 | Mayo's Older African Americans Normative Studies: WMS-R Norms for African American Elders | 2.7 | 24 | Citations (PDF) |
| 768 | Mayo's Older African Americans Normative Studies: Norms for Boston Naming Test, Controlled Oral Word Association, Category Fluency, Animal Naming, Token Test, Wrat-3 Reading, Trail Making Test, Stroop Test, and Judgment of Line Orientation | 2.7 | 181 | Citations (PDF) |
| 769 | Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment | 34.6 | 1,793 | Citations (PDF) |
| 770 | The Effect of tau genotype on clinical features in FTDP-17 | 2.6 | 31 | Citations (PDF) |
| 771 | Mayo's Older African Americans Normative Studies: Normative Data for Commonly Used Clinical Neuropsychological Measures | 2.7 | 102 | Citations (PDF) |
| 772 | Mild cognitive impairment as a diagnostic entity | 7.3 | 7,122 | Citations (PDF) |
| 773 | Genetic variants in a haplotype block spanningIDE are significantly associated with plasma A?42 levels and risk for Alzheimer disease | 4.5 | 94 | Citations (PDF) |
| 774 | An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease | 1.9 | 23 | Citations (PDF) |
| 775 | Hippocampal Volume Is Associated with Memory but not Nonmemory Cognitive Performance in Patients with Mild Cognitive Impairment | 2.4 | 69 | Citations (PDF) |
| 776 | Mild cognitive impairment clinical trials | 79.9 | 161 | Citations (PDF) |
| 777 | Measurement of Cerebrospinal Fluid Flow at the Cerebral Aqueduct by Use of Phase-contrast Magnetic Resonance Imaging: Technique Validation and Utility in Diagnosing Idiopathic Normal Pressure Hydrocephalus | 2.0 | 159 | Citations (PDF) |
| 778 | No association between the lipoprotein lipase S447X polymorphism and Alzheimer's disease | 1.9 | 19 | Citations (PDF) |
| 779 | Interleukin-1A polymorphism is not associated with late onset Alzheimer's disease | 1.9 | 31 | Citations (PDF) |
| 780 | Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers | 1.9 | 12 | Citations (PDF) |
| 781 | An association study of a functional catalase gene polymorphism, −262C→T, and patients with Alzheimer's disease | 1.9 | 41 | Citations (PDF) |
| 782 | Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial | 2.4 | 138 | Citations (PDF) |
| 783 | Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease | 2.9 | 93 | Citations (PDF) |
| 784 | Memory and MRI-based hippocampal volumes in aging and AD | 1.0 | 408 | Citations (PDF) |
| 785 | No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial disease | 1.9 | 42 | Citations (PDF) |
| 786 | AGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE | 2.6 | 125 | Citations (PDF) |
| 787 | REM sleep behavior disorder and dementia | 1.0 | 155 | Citations (PDF) |
| 788 | α-2 macroglobulin gene and Alzheimer disease | 25.2 | 91 | Citations (PDF) |
| 789 | No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease | 1.9 | 48 | Citations (PDF) |
| 790 | Mild Cognitive Impairment | 6.8 | 8,547 | Citations (PDF) |
| 791 | Guamanian neurodegenerative disease: electrophysiologic findings | 2.1 | 12 | Citations (PDF) |
| 792 | Postmenopausal estrogen replacement therapy and risk of AD | 1.0 | 262 | Citations (PDF) |
| 793 | Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease | 6.6 | 180 | Citations (PDF) |
| 794 | Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer's disease but not in healthy control subjects | 1.0 | 177 | Citations (PDF) |
| 795 | Free and cued selective reminding test: Moans norms | 1.0 | 78 | Citations (PDF) |
| 796 | Guamanian neurodegenerative disease: ultrastructural studies of skin | 2.1 | 8 | Citations (PDF) |
| 797 | Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease | 6.6 | 1,355 | Citations (PDF) |
| 798 | The Mini-Mental State Examination in General Medical Practice: Clinical Utility and Acceptance | 3.7 | 239 | Citations (PDF) |
| 799 | Predictive Value of APOE Genotyping in Incipient Alzheimer's Diseasesa | 4.0 | 60 | Citations (PDF) |
| 800 | Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases | 2.1 | 30 | Citations (PDF) |
| 801 | Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO | 2.7 | 509 | Citations (PDF) |
| 802 | No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease | 4.6 | 87 | Citations (PDF) |
| 803 | Tolerance weighted frequency indices for non-cognitive symptoms of dementia 1995, 10, 2-10 | | 6 | Citations (PDF) |
| 804 | Dementia: Diagnosis and Evaluation | 3.7 | 58 | Citations (PDF) |
| 805 | Memory function in very early Alzheimer's disease | 1.0 | 321 | Citations (PDF) |
| 806 | Patterns and Predictors of Institutionalization in Community‐Based Dementia Patients | 2.9 | 133 | Citations (PDF) |
| 807 | Rapidly progressive aphasic dementia and motor neuron disease | 6.6 | 212 | Citations (PDF) |
| 808 | Reply | 6.6 | 0 | Citations (PDF) |
| 809 | Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 | 1.1 | 391 | Citations (PDF) |
| 810 | MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease | 1.0 | 857 | Citations (PDF) |
| 811 | Acute confusional state | 2.6 | 13 | Citations (PDF) |
| 812 | Primary progressive aphasia | 2.2 | 46 | Citations (PDF) |
| 813 | Memory function in normal aging | 1.0 | 229 | Citations (PDF) |
| 814 | Cognitive and Psychiatric Abnormalities in Multiple Sclerosis | 3.7 | 29 | Citations (PDF) |
| 815 | Surgical treatment of idiopathic hydrocephalus in elderly patients | 1.0 | 163 | Citations (PDF) |
| 816 | Title is missing! 0 | | 2 | Citations (PDF) |
| 817 | Title is missing! 0 | | 1 | Citations (PDF) |
| 818 | Title is missing! 0 | | 2 | Citations (PDF) |
| 819 | Title is missing! 0 | | 7 | Citations (PDF) |
| 820 | Title is missing! 0 | | 1 | Citations (PDF) |
| 821 | Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study | 4.6 | 3 | Citations (PDF) |
| 822 | The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging | 33.0 | 36 | Citations (PDF) |
| 823 | Depression and Cognitive Outcomes: Linking the Mayo Clinic Study of Aging and Rochester Epidemiology Project | 2.3 | 0 | Citations (PDF) |
| 824 | Mild Behavioral Impairment: A Population-Based Study | 2.3 | 0 | Citations (PDF) |
| 825 | Predictive Value of Plasma Biomarkers in Tau‐
<scp>PET</scp>
Transitions | 6.6 | 0 | Citations (PDF) |
| 826 | Associations of Chronic Insomnia, Longitudinal Cognitive Outcomes, Amyloid-PET, and White Matter Changes in Cognitively Normal Older Adults | 1.0 | 7 | Citations (PDF) |
| 827 | Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease | 17.6 | 8 | Citations (PDF) |
| 828 | Staging Alzheimer’s disease through amyloid and tau PET | 8.4 | 2 | Citations (PDF) |
| 829 | <scp>MarkVCID2</scp> Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics | 6.6 | 3 | Citations (PDF) |
| 830 | Clinically meaningful changes in cognitive and functional outcomes in a population‐based study of cognitive aging | 4.8 | 0 | Citations (PDF) |
| 831 | Core Clinical Features Associated With Survival in Patients With Dementia With Lewy Bodies | 1.0 | 1 | Citations (PDF) |
| 832 | Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study | 17.9 | 7 | Citations (PDF) |
| 833 | Posterior cortical atrophy: reorganization of the dorsal attention network and its implications on volume loss and clinical performance | 3.4 | 0 | Citations (PDF) |
| 834 | New landscape of the diagnosis of Alzheimer's disease | 62.3 | 24 | Citations (PDF) |
| 835 | Measuring the potential risk of re-identification of imaging research participants from open-source automated face recognition software | 4.4 | 1 | Citations (PDF) |
| 836 | Treatment for Alzheimer's disease | 62.3 | 20 | Citations (PDF) |
| 837 | Alzheimer's disease outlook: controversies and future directions | 62.3 | 15 | Citations (PDF) |
| 838 | Impact of APOE on cerebrovascular lipid profile in Alzheimer’s disease | 9.2 | 1 | Citations (PDF) |
| 839 | The longitudinal association between dyslipidemia and cognitive trajectory | 2.6 | 0 | Citations (PDF) |
| 840 | Association between Human Leukocyte Antigen Alleles and Neuropathological Outcomes in Lewy Body Disease | 6.6 | 0 | Citations (PDF) |
| 841 | 1H-MR spectroscopy biomarkers are associated with plasma-derived biomarkers of amyloid-β and tau in the early phase of AD continuum | 3.4 | 0 | Citations (PDF) |
| 842 | Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study | 17.9 | 3 | Citations (PDF) |
| 843 | Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers | 1.0 | 0 | Citations (PDF) |
| 844 | A Longitudinal Investigation of Prediabetes, Diabetes,
<scp>HbA1c</scp>
and Cognitive Trajectories Among Cognitively Unimpaired Individuals | 2.9 | 0 | Citations (PDF) |
| 845 | Integrating individualized connectome with amyloid pathology improves predictive modeling of future cognitive decline | 4.5 | 1 | Citations (PDF) |
| 846 | Hypergraph clustering for analyzing chronic disease patterns in mild cognitive impairment reversion and progression | 3.4 | 0 | Citations (PDF) |
| 847 | <sup>123</sup>
I-FP-CIT SPECT in Autopsy-Proven Lewy Body Disease 0, 1, | | 0 | Citations (PDF) |
| 848 | A Test of the Alzheimer Disease Framework—Did It Pass? | 17.6 | 1 | Citations (PDF) |
| 849 | Sex differences in cognitive decline and impairment: a scoping review in informatics literature | 4.6 | 0 | Citations (PDF) |
| 850 | Skin Biopsy for Phosphorylated α‐Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice | 4.6 | 0 | Citations (PDF) |
| 851 | Human cerebrospinal fluid net flow enhanced by respiration during the awake state | 13.7 | 0 | Citations (PDF) |
| 852 | Neuroinflammation demonstrated by
11
C‐ER176 PET with amyloid and tau pathology | 0.5 | 0 | Citations (PDF) |
